Evaluación del conocimiento médico sobre la medicina derivada de cannabinoides
Article Sidebar
Main Article Content
Abstract
Objective: To assess the knowledge of medical residents regarding cannabinoid- derived medicine. Methods: An anonymous survey administered to professionals affiliated to medical specialty programs of the Center for Research and Teaching in Health Sciences at the Autonomous University of Sinaloa, based at the Civil Hospital of Culiacán. Results: Of the 71 medical residents surveyed, 93% recognized the medical use of cannabinoids, but 77.5% did not receive professional training on the subject. Consequently, 83.1% did not feel prepared to prescribe them, and 23.9% lacked knowledge about the endocannabinoid system. Additionally, 93% considered medical training in this field necessary. Regarding regulation, 88.7% were unfamiliar with the Reglamento de la Ley General de Salud en Materia de Control Sanitario para la Producción, Investigación y Uso Medicinal de la Cannabis y sus Derivados Farmacológicos (Regulation of the General Health Law on Sanitary Control for the Production, Research, and Medicinal Use of Cannabis and its Pharmacological Derivatives). Conclusion: There is a broad acceptance of the therapeutic use of cannabinoids; however, insufficient training and an unawareness normative among the surveyed medical residents highlight the need to strengthen education in cannabinoid medicine as an emerging theme in Mexico.
Downloads
Article Details
Citas en Dimensions Service
References
Schievenini JD, Pérez RC. Pasado y presente de los usos medicinales del cannabis en México. Redes. 2020;26(50):115–45.
Academia Farmacéutica de México (1846). [Internet]. [citado 2023 Sep 5]. Disponible en: https://books.google.es/books?hl=es&lr=&id=rz4- sAQAAMAAJ&oi=fnd&pg=IA5&dq=farmacopea +mexicana+1846&ots=KYD-BPVE0s&sig=kWuu S-x_FADNvBj6vhU90daiUY8#v=onepage&q=ca nnabis&f=false
Álvarez-Roldán A, Gamella JF, Parra I. La legalización del cannabis: un experimento americano de consecuencias globales. Revista Española de Drogodependencias. 2018;43(4):22-38.
de Souza MR, Henriques AT, Limberger RP. Medical cannabis regulation: an overview of models around the world with emphasis on the Brazilian scenario. J Cannabis Res. 2022;4(1):33.
Presidencia de la República. Diario Oficial de la Federación. 2021 Reglamento de la Ley General de Salud en Materia de Control Sanitario para la Producción, Investigación y Uso Medicinal de la Cannabis y sus Derivados Farmacológicos [Internet]. [citado 2023 Sep 3]. Disponible en: https://dof.gob.mx/nota_detalle.php?codigo=5 609709&fecha=12/01/2021#gsc.tab=0
Weisman JM, Rodríguez M. A systematic review of medical students’ and professionals’ attitudes and knowledge regarding medical cannabis. J Cannabis Res. 2021;3(1):47.
Zolotov Y, Metri S, Calabria E, Kogan M. Medical cannabis education among healthcare trainees: A scoping review. Complement Ther Med. 2021;58:102675.
Abuhasira R, Schleider LBL, Mechoulam R, Novack V. Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly. Eur J Intern Med. 2018;49:44–50.
Dos Santos RG, Hallak JEC, Crippa JAS. Neuropharmacological Effects of the Main Phytocannabinoids: A Narrative Review.Adv Exp Med Biol. 2021;1264:29-45.
Artukoglu BB, Bloch MH. The Potential of Cannabinoid-Based Treatments in Tourette Syndrome. CNS Drugs. 2019;33(5):417–30.
Coghe G, Pau M, Corona F, Frau J, Lorefice L, Fenu G, et al. Walking improvements with nabiximols in patients with multiple sclerosis. J Neurol. 2015;262(11):2472–7.
Müller-Vahl KR. Treatment of Tourette syndrome with cannabinoids. Behavioural Neurology. 2013;27(1):119–24.
McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R, et al. Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial. Am J Psychiatry. 2018;175(3):225–31.
Ranum RM, Whipple MO, Croghan I, Bauer B, Toussaint LL, Vincent A. Use of Cannabidiol in the Management of Insomnia: A Systematic Review. Cannabis Cannabinoid Res. 2023;8(2):213- 229.
Hordowicz M, Jarosz J, Czaplińska M, Leonhard A, Klimkiewicz A. Polish Physicians’ Perspectives on Medical Cannabis Policy and Educational Needs: Results of An Online Survey. J Clin Med. 2021;10(19):4545.
Hordowicz M, Klimkiewicz A, Jarosz J, Wysocka M, Jastrzębska M. Knowledge, attitudes, and prescribing patterns of cannabis and cannabinoid- containing medicines among European healthcare workers: a systematic literature review. Drug Alcohol Depend. 2021;221:108652.
Syed SA, Singh J, Elkholy H, Palavra IR, Tomicevic M, Eric AP, et al. International perspective on physician knowledge, attitude and practices related to medical cannabis. medRxiv [Preprint]. 2023 Jul 27:2023.07.26.23293157.
Isralowitz R, Reznik A, Zolotov Y, Grinstein-Cohen O, Wacht O, Pruginin I, et al. Toward medical cannabis education in Israel. Complement Ther Med. 2021;58:102709.
Gardiner KM, Singleton JA, Sheridan J, Kyle GJ, Nissen LM. Health professional beliefs, knowledge, and concerns surrounding medicinal cannabis – A systematic review. PLoS One. 2019;14(5):e0216556.
Sideris A, Khan F, Boltunova A, Cuff G, Gharibo C, Doan LV. New York Physicians’ Perspectives and Knowledge of the State Medical Marijuana Program. Cannabis Cannabinoid Res. 2018;3(1):74–84.
Cohen K, Weizman A, Weinstein A. Positive and Negative Effects of Cannabis and Cannabinoids on Health. Clin Pharmacol Ther. 2019;105(5):1139–47.
Ziemianski D, Capler R, Tekanoff R, Lacasse A, Luconi F, Ware MA. Cannabis in medicine: a national educational needs assessment among Canadian physicians. BMC Med Educ. 2015;15(1):52.
Häuser W, Finn DP, Kalso E, Krcevski-Skvarc N, Kress HG, Morlion B, et al. European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management. Eur J Pain. 2018;22(9):1547–64.
Observatorio Europeo de las Drogas y las Toxicómanas. Uso médico del cannabis y los cannabinoides: preguntas y respuestas para la elaboración de políticas [Internet]. [citado 2023 Ago 24]. Disponible en: http://hdl.handle. net/10234/187911.
Ashton CH. Adverse effects of cannabis and cannabinoids. Br J Anaesth. 1999;83(4):637–49.
Barrett FS, Schlienz NJ, Lembeck N, Waqas M, Vandrey R. “Hallucinations” Following Acute Cannabis Dosing: A Case Report and Comparison to Other Hallucinogenic Drugs. Cannabis Cannabinoid Res. 2018;3(1):85–93.
LaFrance EM, Stueber A, Glodosky NC, Mauzay D, Cuttler C. Overbaked: assessing and predicting acute adverse reactions to Cannabis. J Cannabis Res. 2020;2(1):3.
Hjorthøj C, Compton W, Starzer M, Nordholm D, Einstein E, Erlangsen A, et al. Association between cannabis use disorder and schizophrenia stronger in young males than in females. Psychol Med. 2023; 53(15):7322-7328.
González-González M del R, Yeverino-Gutiérrez ML, González-Santiago O. Attitudes toward medicinal marijuana in metropolitan Monterrey, Mexico. Salud Publica Mex. 2018;60(2):120–2.
Camberos-Barraza J, Osuna-Ramos JF, Rábago- Monzón AR, Quiñonez-Angulo LF, González- Peña HR, Pérez-Ramos AA, et al. Scientific facts improve cannabis perception and public opinion: results from Sinaloa, México. Sci Rep. 2023;13(1):17318.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.